Abstract Library
Members may log into MY ENETS to visit the abstract library from previous ENETS conferences.
Participants of the ENETS Conference in 2024 can now access the abstract booklet, e-posters and videos, slide decks of talks, the poster carousel, and more via My ENETS.
ENETS Abstract Search
Introduction: Peptide receptor radionuclide therapy (PRRT) usually leads to stable rather than decreased lesion size in neuroendocrine tumors (NETs), therefore RECIST criteria are not used to assess early response to treatment.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Fisher G, Franc B, Moradi F,
Keywords: PRRT, 68Ga-DOTATATE PET/CT, Neuroendocrine tumor,
Introduction: 177Lu-DOTATATE is an effective therapy for somatostatin receptor-positive neuroendocrine tumors (NETs). Often enough 177Lu-DOTATATE is used as the last treatment resort in advanced NET.
Conference: 17th Annual ENETSConcerence (2020)
Presenting Author:
Authors: Song H, Kunz P, Franc B, Moradi F, Fisher G,
Keywords: 177Lu-DOTATATE, PRRT, 68Ga-DOTATATE PET, Chromogranin A, 68Ga-DOTATATE avid tumor volume,
Introduction: Bulky disease from NET is an adverse prognostic factor for response to 177Lu-DOTA-octreotate (LuTate) PRCRT. 90Y-DOTA-octreotate (YTate) has more penetrating particulate emissions.
Conference: 13th Annual ENETSConcerence (2016)
Presenting Author:
Authors: Kong G, Callahan J, Hofman M, Pattison D, Akhurst T,